Generate:Biomedicines Announces Multi-Target Collaboration With Novartis to Discover And Develop Protein Therapeutics with Generative AI

Generate

Insider Brief

  • Generate announced a multi-target collaboration with Novartis to create and develop protein therapeutics using generative AI.
  • The partnership combines Generate’s AI platform with Novartis’ expertise in biologics and clinical development to accelerate drug discovery.
  • Generate will receive $65 million upfront, with potential for over $1 billion in milestone payments and royalties based on the success of the collaboration.

PRESS RELEASE — Generate:Biomedicines (“Generate”) today announced a multi-target collaboration with Novartis (NYSENVS) to discover and develop protein therapeutics across multiple disease areas. The collaboration leverages Generate’s proprietary generative AI platform, ​The Generate Platform,” to create potentially first- and best-in-class molecules through AI-based optimization and de novo generation.

The collaboration will combine The Generate Platform, which integrates machine learning with high-throughput experimental validation, with Novartis expertise and capabilities in target biology, biologics development, and clinical development to create novel therapeutics and to accelerate the pace of drug discovery and development.

We are delighted to collaborate with Generate to explore the promise of generative AI in enhancing and accelerating the discovery of next-generation biologics,” said Fiona Marshall, President of Biomedical Research at Novartis. ​This collaboration offers an opportunity to leverage the unique strengths of our respective companies, from target biology and biologics discovery to machine learning/​AI and clinical development, in order to bring forward new medicines with transformative potential for patients.”

Partnering with a world-leading drug discovery and development organization like Novartis allows us to broaden the use of our cutting-edge generative biology platform to tackle even more areas of unmet medical need,” said Mike Nally, Chief Executive Officer of Generate:Biomedicines. ​We look forward to working closely with the team at Novartis to continue to demonstrate the transformative potential of programming biology to create better medicines for patients, faster.”

Under the terms of the collaboration agreement, Generate will receive a total upfront payment of $65 million in cash from Novartis, which includes $15 million for the purchase of equity in Generate. Generate is also eligible to receive more than $1 billion in performance-based milestone payments, in addition to tiered royalties up to low double-digits. The number of targets and therapeutic areas are not being disclosed.

AI Insider

Discover the future of AI technology with "AI Insider" - your go-to platform for industry data, market insights, and groundbreaking AI news

Subscribe today for the latest news about the AI landscape